NCT05949775View on ClinicalTrials.gov

Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors

NANot yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

December 12, 2025

Study Completion Date

March 20, 2026

Conditions
Advanced Malignant Solid Tumors
Interventions
BIOLOGICAL

Neoantigen mRNA Personalised Cancer vaccine

Drug: Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab Injection Subcutaneous Injection

All Listed Sponsors
collaborator

Peking University Cancer Hospital & Institute

OTHER

lead

Stemirna Therapeutics

INDUSTRY

NCT05949775 - Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors | Biotech Hunter | Biotech Hunter